These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22298944)

  • 1. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland.
    D'Arcy C; Thomas D; Stoneman D; Parkes L
    Patient Prefer Adherence; 2012; 6():55-61. PubMed ID: 22298944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
    Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
    BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study.
    Järvinen E; Multanen J; Atula S
    Neurol Int; 2017 Feb; 9(1):6957. PubMed ID: 28286627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
    Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
    Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
    Wray S; Hayward B; Dangond F; Singer B
    Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device.
    Willis H; Webster J; Larkin AM; Parkes L
    Patient Prefer Adherence; 2014; 8():843-51. PubMed ID: 24966669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study).
    Pedersen ED; Stenager E; Vadgaard JL; Jensen MB; Schmid R; Meland N; Magnussen G; Frederiksen JL
    Patient Prefer Adherence; 2018; 12():569-575. PubMed ID: 29720872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
    Devonshire VA; Feinstein A; Moriarty P
    BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
    Centonze D; Fantozzi R; Buttari F; Grimaldi LME; Totaro R; Corea F; Marrosu MG; Confalonieri P; Cottone S; Trojano M; Zipoli V
    Front Neurol; 2021; 12():637615. PubMed ID: 33967938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
    Ghezzi A; Bianchi A; Baroncini D; Bertolotto A; Malucchi S; Bresciamorra V; Lanzillo R; Milani N; Martinelli V; Patti F; Chisari C; Rottoli M; Simone M; Paolicelli D; Visconti A;
    Neurol Sci; 2017 Nov; 38(11):1999-2005. PubMed ID: 28831635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
    Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
    Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
    Lugaresi A; De Robertis F; Clerico M; Brescia Morra V; Centonze D; Borghesan S; Maniscalco GT;
    Expert Opin Drug Deliv; 2016 Jul; 13(7):931-5. PubMed ID: 26909646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
    Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
    Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.